The Fraunhofer Institute for Translational Medicine and Pharmacology ITMP investigates and develops innovative ways of early detection, diagnosis and treatment of diseases resulting from impaired function of the immune system.

It comprises three research areas “Drug Discovery”, “Preclinical Research” and “Clinical Research”. Fraunhofer ITMP is a competent partner for universities, for translating medical research findings into valuable assets, as well as for the pharmaceutical and biotechnological industry.

The institute currently employs about 237 people at its locations Frankfurt am Main, Hamburg, Göttingen, Berlin and Penzberg/Munich. It is scientifically closely linked to a large number of institutes and clinics of the University Hospital of the Goethe University Frankfurt am Main, the University Hospital Hamburg-Eppendorf, the University Medical Center Göttingen, the Charité, the Ludwig-Maximilians-University and the LMU Medical Center. We also have extensive scientific collaborations with other national and international universities and research institutions. The aim of these are to identify trends and developments at an early stage and to develop and implement new research approaches and technologies. Within the Fraunhofer-Gesellschaft, we provide expertise to the MED2ICIN lighthouse project and lead the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD.

Our research and development services are aimed at industry, small and medium-sized enterprises and the public sector. The interdisciplinary nature of the institute enables it to proficiently progress complex cross-sectoral projects with external institutes and partners. We have a solid international network and track record of successfully advancing a wide range projects. Our state-of-the-art laboratories offer a wide range of research and technology services and our interdisciplinary teams implement innovative preclinical and clinical trials according to the highest quality standards.

The Frankfurt am Main site has expertise in pharmacology and clinical trials. The Hamburg site is one of the world's leading institutions for identifying pharmacologically active substances using screening methodologies. The Göttingen site is focused on translational research in the field of neuroinflammation as well as on nanomicroscopy. The Berlin site aims to develop better solutions for patients with allergies and other mast cell-driven diseases. The research focus of the Penzberg/Munich site is on translational and clinical aspects of immunology, infectious disease and pandemic research.



Network and Cooperationen

Board of Trustees